Determinants of HIV shedding in the lower genital tract of women

Current Infectious Disease Reports

Volumn 10, Issue 6, 2008, Pages 505-511

  Anderson, Brenna L ^a   Cu Uvin, Susan ^b  

^a WOMEN AND INFANTS HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; CONTRACEPTIVE AGENT; EFAVIRENZ; LAMIVUDINE; MULTIVITAMIN; NUCLEOSIDE ANALOG; PLACEBO; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SELENIUM; TENOFOVIR; VALACICLOVIR; ZIDOVUDINE;

CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG PENETRATION; DRUG TISSUE LEVEL; ENDOMETRITIS; FEMALE; FEMALE GENITAL SYSTEM; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HETEROSEXUALITY; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; LACTOBACILLUS; MIXED INFECTION; NONHUMAN; PATHOGENESIS; REVIEW; RISK FACTOR; SEXUAL TRANSMISSION; VIREMIA; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS TRANSMISSION; VITAMIN SUPPLEMENTATION;

EID: 63249113029     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-008-0082-z     Document Type: Review

References (50)

1. World Health Organization: The 10 leading causes of death by broad income group (2005 projections). Available at http://www.who.int/ mediacentre/factsheets/fs310/en/index4.html. Accessed May 2008.
2. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adult and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Accessed June 9, 2008.
3. Vettore MV, Schechter M, Melo MF, et al.: Genital HIV-1 viral load is correlated with blood plasma HIV-1 viral load in Brazilian women and is reduced by antiretroviral therapy. J Infect 2006, 52:290-293.
4. Cu-Uvin S, Snyder B, Harwell JI, et al.: Association between paired plasma and cervicovaginal lavage fluid HIV-1 RNA levels during 36 months. J Acquir Immune Defic Syndr 2006, 42:584-587.
5. Lalani T, Hicks C: Does antiretroviral therapy prevent HIV transmission to sexual partners? Curr HIV/AIDS Rep 2007, 4:80-85.
6. Quinn TC, Wawer MJ, Sewankambo N, et al.: Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000, 342:921-929.
7. Cohen MS, GaA C, Kashuba ADM, et al.: Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 2007, 146:591-601.
8. Chaudry NI, Eron JJ, Naderer OJ, et al.: Effects of formulation and dosing strategy on amprenavir concentrations in the seminal plasma of human immunodeficiency virus type 1-infected men. Clin Infect Dis 2002, 35:760-762.
9. Ghosn J, Chaix M-L, Peytavin G, et al.: Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS 2004, 18:1958-1961.
10. Min SS, Corbett AH, Rezk N, et al.: Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women. J Acquir Immune Defic Syndr 2004, 37:1577-1580.
11. Taylor S, van Heeswijk RP, Hoetelmans RM, et al.: Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men. AIDS 2000, 14:1979-1984.
12. van Praag RM, van Heeswijk RP, Jurriaans S, et al.: Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1. Clin Infect Dis 2001, 33:e91-e92.
13. Graham SM, Holte SE, Peshu NM, et al.: Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding. AIDS 2007, 21:501-507.
14. Neely MN, Benning L, Xu J, et al.: Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2007, 44:38-42.
15. Taylor S, Pereira AS: Antiretroviral drug concentrations in semen of HIV-1 infected men. Sex Transm Infect 2001, 77:4-11.
16. Dumond JB, Yeh RF, Patterson KB, et al.: Antiretroviral drug exposure in the female genital tract: Implications for oral pre-and post-exposure prophylaxis. AIDS 2007, 21:1899-1907.
17. Kwara A, DeLong AK, Rezk N, et al.: Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. Clin Infect Dis 2008, 46:719-725.
18. Andreoletti L, Skrabal K, Perrin V, et al.: Genetic and phenotypic features of blood and genital viral populations of clinically asymptomatic and antiretroviral-treatment-naive clade A human immunodeficiency virus type 1-infected women. J Clin Microbiol 2007, 45:1838-1842.
19. Chomont N, Hocini H, Grésenguet G, et al.: Early archives of genetically-restricted proviral DNA in the female genital tract after heterosexual transmission of HIV-1. AIDS 2007, 21:153-162.
20. Kemal KS, Burger H, Mayers D, et al.: HIV-1 drug resistance in variants from the female genital tract and plasma. J Infect Dis 2007, 195:535-545.
21. Zárate S, Pond SLK, Shapshak P, Frost SDW: Comparative study of methods for detecting sequence compartmentalization in human immunodeficiency virus type 1. J Virol 2007, 81:6643-6651.
22. Yeaman GR, White HD, Howell A, et al.: The mucosal immune system in the human female reproductive tract: Potential insights into the heterosexual transmission of HIV. AIDS Res Hum Retroviruses 1998, 14(Suppl 1):S57-S62.
23. Wira CR, Fahey JV: A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle. AIDS 2008, in press.
24. Mestecky J: Humoral immune responses to the human immunodeficiency virus type-1 (HIV-1) in the genital tract compared to other mucosal sites. J Reprod Immunol 2007, 73:86-97.
25. Coleman JS, Hitti J, Bukusi EA, et al.: Infectious correlates of HIV-1 shedding in the female upper and lower genital tracts. AIDS 2007, 21:755-759.
26. Clark RA, Theall KP, Amedee AM, Kissinger PJ: Frequent douching and clinical outcomes among HIV-infected women. Sex Transm Dis 2007, 34:985-990.
27. Royce RA, Sena A, Cates W, Cohen MS: Sexual transmission of HIV. N Engl J Med 1997, 336:1072-1078.
28. Kaul R, Pettengell C, Sheth PM, et al.: The genital tract immune milieu: an important determinant of HIV susceptibility and secondary transmission. J Reprod Immunol 2008, 77:32-40.
29. Baeten JM, McClelland RS, Corey L, et al.: Vitamin A supplementation and genital shedding of herpes simplex virus among HIV-1-infected women: A randomized clinical trial. J Infect Dis 2004, 189:1466-1471.
30. McClelland RS, Wang CC, Overbaugh J, et al.: Association between cervical shedding of herpes simplex virus and HIV-1. AIDS 2002, 16:2425-2430.
31. Cohen MS, Hoffman IF, Royce RA, et al.: Reduction of concentration of HIV-1 in semen after treatment of urethritis: Implications for prevention of sexual transmission of HIV-1. Lancet 1997, 349:1868-1873.
32. Price MA, Zimba D, Hoffman IF, et al.: Addition of treatment for trichomoniasis to syndromic management of urethritis in Malawi: A randomized clinical trial. Sex Transm Dis 2003, 30:516-522.
33. LeGoff J, Weiss HA, Gresenguet G, et al.: Cervicovaginal HIV-1 and herpes simplex virus type 2 shedding during genital ulcer disease episodes. AIDS 2007, 21:1569-1578.
34. Rebbapragada A, Wachihi C, Pettengell C, et al.: Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract. AIDS 2007, 21:589-598.
35. Nagot N, Ouedraogo A, Foulongne V, et al.: Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007, 356:790-799.
36. Baeten JM, Strick L, Lucchetti A, et al.: Herpes simplex virus suppressive treatment decreases plasma and genital HIV-1 viral loads in HSV-2/HIV-1 co-infected women: A randomized, placebo-controlled crossover trial. Presented at 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 3-6, 2008.
37. Watson-Jones D, Weiss HA, Rusizoka M, et al.: Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008, 358:1560-1571.
38. Celum C, Wald A, Hughes J, et al.: HSV-2 suppressive therapy for prevention of HIV acquisition: Results of HPTN 039. Presented at 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 3-6, 2008.
39. Fox-Canale AM, Hope TJ, Martinson J, et al.: Human cytomegalovirus and human immunodeficiency virus type-1 co-infection in human cervical tissue. Virology 2007, 369:55-68.
40. Perinatal HIV Guidelines Working Group: Public Health Service task force recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available at http://aidsinfo.nih.gov/ ContentFiles/PerinatalGL.pdf. Accessed June 9, 2008.
41. Fawzi W, Msamanga G, Antelman G, et al.: Effect of prenatal vitamin supplementation on lower-genital levels of HIV type 1 and interleukin type 1 beta at 36 weeks of gestation. Clin Infect Dis 2004, 38:716-722.
42. Fawzi WW, Msamanga G, Hunter D, et al.: Randomized trial of vitamin supplements in relation to vertical transmission of HIV-1 in Tanzania. J Acquir Immune Defic Syndr 2000, 23:246-254.
43. McClelland RS, Baeten JM, Overbaugh J, et al.: Micronutrient supplementation increases genital tract shedding of HIV-1 in women: results of a randomized trial. J Acquir Immune Defic Syndr 2004, 37:1657-1663.
44. Baeten JM, Mostad SB, Hughes MP, et al.: Selenium deficiency is associated with shedding of HIV-1-infected cells in the female genital tract. J Acquir Immune Defic Syndr 2001, 26:360-364.
45. Kupka R, Garland M, Msamanga G, et al.: Selenium status, pregnancy outcomes, and mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr 2005, 39:203-210.
46. Kupka R, Msamanga GI, Xu C, et al.: Relationship between plasma selenium concentrations and lower genital tract levels of HIV-1 RNA and interleukin type 1beta. Eur J Clin Nutr 2007, 61:542-547.
47. Stringer EM, Kaseba C, Levy J, et al.: A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol 2007, 197(2):144.e1-144.e8.
48. Clark RA, Theall KP, Amedee AM, et al.: Lack of association between genital tract HIV-1 RNA shedding and hormonal contraceptive use in a cohort of Louisiana women. Sex Transm Dis 2007, 34:870-872.
49. Losikoff P, Fichorova R, Snyder B, et al.: Genital tract interleukin-8 but not interleukin-1beta or interleukin-6 concentration is associated with bacterial vaginosis and its clearance in HIV-infected and HIV-uninfected women. Infect Dis Obstet Gynecol 2007, 15:1-6.
50. Coombs RW, Wright DJ, Reichelderfer PS, et al.: Variation of human immunodeficiency virus type 1 viral RNA levels in the female genital tract: Implications for applying measurements to individual women. J Infect Dis 2001, 184:1187-1191.